RecruitingNot applicableNCT05535361
A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome
Studying Congenital short bowel syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Eclipse Regenesis, Inc.
- Intervention
- Distraction Enterogenesis in Adult Patients with Short Bowel Syndrome(device)
- Enrollment
- 40 enrolled
- Eligibility
- 65 years · All sexes
- Timeline
- 2025 – 2028
Study locations (6)
- Lucile Packard Children's Hospital Stanford, Palo Alto, California, United States
- University of California San Francisco, San Francisco, California, United States
- Stanford University School of Medicine, Stanford, California, United States
- Children's National Hospital, Washington D.C., District of Columbia, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Cincinnati Children's Hospital, Cincinnati, Ohio, United States
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Children's Hospital Medical Center, Cincinnati · Stanford University · University of California, San Francisco · Boston Children's Hospital · Lucile Packard Children's Hospital at Stanford · Children's National Health System, Washington DC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05535361 on ClinicalTrials.gov